An interventional study of Lumbar Sympathetic Ganglion Block in Chronic Pain, Complex Regional Pain Syndromes and Peripheral Neuropathy, sponsored by Jeongsoo Kim. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-11.
Sponsored by Jeongsoo Kim · Not applicable, Interventional, and Treatment
Among 36 studies in Chronic Pain with a site in Korea, Republic of — 10 open to participants now, 11 under way, none of them phase 3. Chronic Pain · Korea, Republic of.
Among the 36 studies in Chronic Pain with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2024, is one of 22 with no phase, and was the 28th registered.
3,227 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →10 of the 36 studies in Chronic Pain with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Jaseng Medical Foundation · Sites in Korea, Republic of
Ages 19–70
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–79
Korea University · Sites in Korea, Republic of
Ages 60+ · Healthy volunteers
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 20–80
Sahmyook University · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 19 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 2,387 interventional studies indexed under Chronic Pain.
Median enrollment 76 across the 28 interventional studies, 89 across the 8 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jeongsoo Kim as lead sponsor.
Jeongsoo Kim has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Chronic Pain with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06270121Sunmi SongDevelopment of a Healthcare Service Platform for Successful Aging | 2026-11-30 |
| NCT07832318Jaseng Medical FoundationEffectiveness and Safety of Pharmacopuncture Therapy for Chronic Lumbar Radiculopathy: A Multicenter, Pragmatic, Randomized, Comparative Clinical Trial | 2026-12 |
| NCT07917702Gwangju Health UniversityEffects of Transcranial Direct Current Stimulation and Manual Therapy on Musculoskeletal Pain in Adolescent Dancers | 2026-12-09 |
| NCT07485387Korea UniversityGlobal Collaborative Research on Establishing a Korean Cognitive Aging Cohort | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Chronic Pain with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The patient, who is experiencing chronic pain in the lower extremities persisting for more than three months, is scheduled to undergo lumbar sympathetic ganglion block. To evaluate the technical success of the sympathetic blockade, temperature and perfusion index (PI) will be measured at one-minute intervals over a 20-minute period before and after the procedure on the treated side and the opposite side foot. Additionally, other variables related to the procedure will be assessed before the procedure, after the procedure, before discharge, and during follow-up outpatient visits or phone surveys at 1 week and 1 month after the procedure.
Patients aged 19 to 85 experiencing lower limb pain and scheduled to undergo lumbar sympathetic ganglion block at the Seoul National University Hospital Pain Center will be directly informed about the study, and their participation will be sought and registered. Continuous monitoring of electrocardiography, blood pressure, and pulse oximetry will be conducted before and after the procedure.
Upon admission to the pain center's operating room, the patient will assume a prone position. Thermometers will be attached to the soles of both feet, and perfusion index probes will be attached to the second toe on both sides. Using fluoroscopy guidance, a needle will be inserted at the painful side, either right or left, at the L3. After confirming the needle's position in front of the desired vertebral body using contrast medium in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected. Baseline temperature and PI values will be recorded before drug administration, followed by recording every minute for 20 minutes after injection.
Other variables related to the procedure will be assessed before and after the procedure, before discharge, and through outpatient visits or phone surveys at one week after the procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
FS-guided LSGB at L3 level.
Procedure: Lumbar Sympathetic Ganglion Block
A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
Difference of perfusion index (%)
Difference of perfusion index (%) between ipsilateral foot and contralateral foot
Time frame: before and 1 - 20 minutes after FS-guided lumbar sympathetic ganglion block
Difference of temperature change (°C)
Difference of temperature change (°C) between ipsilateral foot and contralateral foot
Time frame: before and 1 - 20 minutes after FS-guided lumbar sympathetic ganglion block
Severity of pain
11-point Numerical Rating Scale (NRS, 0-10)
Time frame: Time before block and 20 minutes, 1 week, 4 weeks after FS-guided lumbar sympathetic ganglion block ( The higher the score, the more severe the pain)
Proportion of patients reaching ≥ 1.5°C rise
Proportion of patients reaching ≥ 1.5°C rise of temperature in the ipsilateral foot compared to the contralateral foot
Time frame: 20 minutes after FS-guided lumbar sympathetic ganglion block
Proportion of patients reaching ≥ 2.0°C rise
Proportion of patients reaching ≥ 2.0°C rise of temperature in the ipsilateral foot compared to initial temperature in the ipsilateral foot
Time frame: 20 minutes after FS-guided lumbar sympathetic ganglion block
Proportion of patients reaching ≥ 100% rise of perfusion index (%)
Proportion of patients reaching ≥ 100% rise of perfusion index (%) in the ipsilateral foot compared to the initial perfusion index (%) in the ipsilateral foot
Time frame: 1 - 20 minutes after FS-guided lumbar sympathetic ganglion block
Patient satisfaction
Patient Global Impression of Change (1-5)
Time frame: Time 20 minutes, 1 week, 4 weeks after FS-guided lumbar sympathetic ganglion block (The higher the score, the higher the satisfaction)
Plan to share: No
Ran from Feb 2024 to primary completion in Apr 2024, 2 months.
Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 2 months is below that.
Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.